Artiva Biotherapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Artiva Biotherapeutics, Inc. (ARTV) reported Basic Shares Outstanding (Weighted Average) of 39.41 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 39.41M shares, a 61.67% increase year-over-year.
- Artiva Biotherapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 24.68M shares, a 1.38% increase year-over-year.
- Artiva Biotherapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 24.57M shares, a 0.77% increase year-over-year.
- Artiva Biotherapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 24.48M shares, a 29.55% increase year-over-year.
- Artiva Biotherapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 24.44M shares, a 117.11% increase from fiscal 2024.
- Artiva Biotherapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 11.26M shares, a 1302.54% increase from fiscal 2023.
- Artiva Biotherapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 802.75K shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 39.41M shares 10-Q · filed 2026-08-06 | 32.09M shares 10-Q · filed 2026-08-06 | 29.55M shares derived: average of 3 quarters · filed 2026-08-06 | 28.29M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 24.68M shares 10-Q · filed 2026-05-08 | 24.63M shares derived: average of 2 quarters · filed 2026-05-08 | 24.58M shares derived: average of 3 quarters · filed 2026-05-08 | 24.53M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 24.57M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 24.53M shares derived: average of 2 quarters · filed 2026-03-10 | 24.48M shares derived: average of 3 quarters · filed 2026-08-06 | 24.44M shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 24.48M shares 10-Q · filed 2025-11-12 | 24.43M shares derived: average of 2 quarters · filed 2026-08-06 | 24.40M shares 10-Q · filed 2025-11-12 | 24.40M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 24.38M shares 10-Q · filed 2026-08-06 | 24.36M shares 10-Q · filed 2026-08-06 | 24.37M shares derived: average of 3 quarters · filed 2026-08-06 | 23.00M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 24.34M shares 10-Q · filed 2026-05-08 | 24.36M shares derived: average of 2 quarters · filed 2026-05-08 | 22.54M shares derived: average of 3 quarters · filed 2026-05-08 | 17.11M shares derived: average of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | 24.39M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 21.64M shares derived: average of 2 quarters · filed 2026-03-10 | 14.70M shares derived: average of 3 quarters · filed 2026-03-10 | 11.26M shares 10-K · filed 2026-03-10 |
| 2024-09-30 | 18.90M shares 10-Q · filed 2025-11-12 | 9.85M shares derived: average of 2 quarters · filed 2025-11-12 | 6.88M shares 10-Q · filed 2025-11-12 | 5.33M shares derived: average of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | 811.21K shares 10-Q · filed 2025-08-06 | 810.48K shares 10-Q · filed 2025-08-06 | 810.11K shares derived: average of 3 quarters · filed 2025-08-06 | 809.26K shares derived: average of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | 809.76K shares 10-Q · filed 2025-05-08 | 809.56K shares derived: average of 2 quarters · filed 2025-05-08 | 808.61K shares derived: average of 3 quarters · filed 2025-05-08 | 806.68K shares derived: average of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | 809.37K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | 808.04K shares derived: average of 2 quarters · filed 2025-03-24 | 805.66K shares derived: average of 3 quarters · filed 2025-03-24 | 802.75K shares 10-K · filed 2025-03-24 |
| 2023-09-30 | 806.71K shares 10-Q · filed 2024-11-12 | 803.80K shares derived: average of 2 quarters · filed 2024-11-12 | 800.54K shares 10-Q · filed 2024-11-12 | |
| 2023-06-30 | 800.89K shares 10-Q · filed 2024-08-29 | 797.40K shares 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |